CS and metabolic dysfunction-associated steatotic liver disease: MASLD development in the GDM mice occurred in conjunction with significant reductions in hepatic mitochondrial activity at day 6.5 (citrate synthase, p<0.01) and day 17.5 (β-HAD, citrate synthase, P<0.001) compared to CD mice.